PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27926506-5	2017	When scar fibroblasts were pre-treated with PSC833 or probenecid, a P-glycoprotein or MRP1 inhibitor respectively, the resistance to verapamil or etoposide was strongly attenuated.	Probenecid	54-64	ATP binding cassette subfamily B member 1	Homo sapiens	68-82	
21636258-1	2011	The expressions of P-glycoprotein (P-gp) and multidrug resistance-associated proteins (MRPs) in the blood-brain barrier (BBB) were regulated by verapamil and probenecid.	Probenecid	158-168	ATP binding cassette subfamily B member 1	Homo sapiens	19-33	
21636258-1	2011	The expressions of P-glycoprotein (P-gp) and multidrug resistance-associated proteins (MRPs) in the blood-brain barrier (BBB) were regulated by verapamil and probenecid.	Probenecid	158-168	ATP binding cassette subfamily B member 1	Homo sapiens	35-39	
21636258-5	2011	The culture using ACM negligibly affected the activity of P-gp and MRPs on HBMECs after the suppression with verapamil and/or probenecid.	Probenecid	126-136	ATP binding cassette subfamily B member 1	Homo sapiens	58-62	
11587213-4	2001	A fluorescent probe assay using Syto16/PSC833 and calcein-AM/probenecid as substrate/modulator of the Pgp and MRP pump, respectively, and subsequent labeling of cells with monoclonal antibodies for LAP detection allowed simultaneous detection of LAP and Pgp or MRP activity.	Probenecid	61-71	ATP binding cassette subfamily B member 1	Homo sapiens	102-105	
21629661-6	2011	Probenecid is an FDA-approved inhibitor of the Multidrug Resistance Protein 1 (MRP1) transporter and is clinically used to treat gout in humans.	Probenecid	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	47-77	
21629661-6	2011	Probenecid is an FDA-approved inhibitor of the Multidrug Resistance Protein 1 (MRP1) transporter and is clinically used to treat gout in humans.	Probenecid	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	79-83	
18576903-15	2008	Renal clearance of dicloxacillin was significantly reduced in the presence of probenecid but not with cyclosporine, suggesting that the rate-limiting step in tubular secretion of dicloxacillin is uptake mediated by the organic anion transporter, and not P-glycoprotein inhibition.	Probenecid	78-88	ATP binding cassette subfamily B member 1	Homo sapiens	254-268	
18195111-5	2008	Maternofetal permeability was increased by the ABCC2 inhibitor probenecid (0.59 +/- 0.15 versus 0.68 +/- 0.13, p = 0.028) and the nonspecific inhibitor verapamil (0.53 +/- 0.09 versus 0.66 +/- 0.16, p = 0.028) but was not influenced by the ABCB1 inhibitor valspodar (PSC833) (0.48 +/- 0.11 versus 0.46 +/- 0.09, p = 0.345).	Probenecid	63-73	ATP binding cassette subfamily B member 1	Homo sapiens	240-245	
8636432-6	1996	Sulfinpyrazone and probenecid, known inhibitors of multispecific organic anion transport, inhibited this basolateral transport, but not the apical transport of daunorubicin mediated by the apically localized human MDR1 P-glycoprotein in MDR1-transfected LLC-PK1 cells.	Probenecid	19-29	ATP binding cassette subfamily B member 1	Homo sapiens	237-241	
9182837-1	1997	PURPOSE: To determine whether probenecid, an inhibitor of organic anion transport, is able to reverse multidrug resistance (MDR) through modulation of the drug transport function of MDR-associated protein (MRP) and P-glycoprotein (P-gP).	Probenecid	30-40	ATP binding cassette subfamily B member 1	Homo sapiens	215-229	
9182837-1	1997	PURPOSE: To determine whether probenecid, an inhibitor of organic anion transport, is able to reverse multidrug resistance (MDR) through modulation of the drug transport function of MDR-associated protein (MRP) and P-glycoprotein (P-gP).	Probenecid	30-40	ATP binding cassette subfamily B member 1	Homo sapiens	231-235	
11356921-4	2001	Fluorescein/probenecid and quinidine/LY-335979 were chosen as the substrate/inhibitor combinations for organic anion transport and P-glycoprotein-medicated transport, respectively.	Probenecid	12-22	ATP binding cassette subfamily B member 1	Homo sapiens	131-145	
11118294-2	2000	Using specific substrate efflux assay, we show that GF120918 (0.2 microM) and probenecid (5 mM) were specific inhibitors of MDR1 and MRP1, respectively.	Probenecid	78-88	ATP binding cassette subfamily B member 1	Homo sapiens	124-128	
9506530-6	1998	The P-glycoprotein-mediated multidrug resistance (MDR)-reversing agents verapamil, cyclosporin A, quinidine, sodium orthovanadate and tamoxifen significantly increased dox fluorescence at this depth, whereas genistein, indomethacin, probenecid and brefeldin A, which reverse multidrug-resistance-associated protein (MRP) function, exerted no effect.	Probenecid	233-243	ATP binding cassette subfamily B member 1	Homo sapiens	4-18